Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study with more frequent and higher doses of RADICAVA for treatment of amyotrophic lateral sclerosis (ALS)

Trial Profile

A clinical study with more frequent and higher doses of RADICAVA for treatment of amyotrophic lateral sclerosis (ALS)

Status: Planning
Phase of Trial: Phase IV

Latest Information Update: 28 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edaravone (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Aug 2018 New trial record
    • 08 Aug 2018 According to a Mitsubishi Tanabe Pharma America media release, the company is working with the US FDA to conduct a post-marketing commitment study to understand of the effect of more frequent and higher doses of RADICAVA on ALS. This post-marketing commitment study includes 1) Pharmacokinetics study in patients with severe hepatic impairment (298980) 2) QT/QTc evaluation in healthy subjects (299043). 3)Clinical study with more frequent and higher doses of RADICAVA for at least 24 weeks (299046).
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top